Investors Purchase High Volume of BioNTech Call Options (NASDAQ:BNTX)

BioNTech SE (NASDAQ:BNTXGet Free Report) saw some unusual options trading on Tuesday. Investors acquired 3,757 call options on the stock. This represents an increase of 74% compared to the typical volume of 2,154 call options.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on BNTX. UBS Group cut their price objective on BioNTech from $110.00 to $101.00 and set a “neutral” rating for the company in a research report on Wednesday, March 27th. BMO Capital Markets cut their price objective on BioNTech from $123.00 to $122.00 and set an “outperform” rating for the company in a research report on Tuesday, May 7th. Evercore ISI began coverage on BioNTech in a research report on Tuesday, May 14th. They issued an “inline” rating and a $100.00 price objective for the company. TD Cowen boosted their price objective on BioNTech from $95.00 to $98.00 and gave the company a “hold” rating in a research report on Tuesday, May 7th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $171.00 price objective on shares of BioNTech in a research report on Thursday, March 21st. One analyst has rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $111.70.

Check Out Our Latest Report on BioNTech

Hedge Funds Weigh In On BioNTech

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BNTX. GAMMA Investing LLC lifted its stake in shares of BioNTech by 86.9% in the 2nd quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock valued at $41,000 after purchasing an additional 238 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after purchasing an additional 252 shares during the last quarter. Tidal Investments LLC acquired a new position in shares of BioNTech in the 1st quarter valued at $703,000. Dynasty Wealth Management LLC acquired a new position in shares of BioNTech in the 1st quarter valued at $391,000. Finally, Bamco Inc. NY lifted its stake in shares of BioNTech by 3.7% in the 1st quarter. Bamco Inc. NY now owns 251,223 shares of the company’s stock valued at $23,175,000 after purchasing an additional 8,875 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Stock Performance

NASDAQ BNTX opened at $81.30 on Thursday. The stock’s fifty day moving average is $90.91 and its two-hundred day moving average is $93.38. The firm has a market capitalization of $19.33 billion, a P/E ratio of 162.60 and a beta of 0.23. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.16 and a current ratio of 11.38. BioNTech has a fifty-two week low of $78.02 and a fifty-two week high of $125.83.

BioNTech (NASDAQ:BNTXGet Free Report) last released its quarterly earnings data on Monday, May 6th. The company reported ($1.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.60). The company had revenue of $203.69 million for the quarter, compared to analyst estimates of $589.96 million. BioNTech had a return on equity of 0.55% and a net margin of 4.01%. On average, research analysts anticipate that BioNTech will post -2 earnings per share for the current year.

About BioNTech

(Get Free Report)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

Further Reading

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.